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Introduction
According to the European recommendations (version
5.2., November 2009) at patients with the HIV-infection
and chronic hepatitis B (CHB), not receiving HAART,
adefovir and LdT may be used as an alternative regime.
In the Russian Federation adefovir is not registered and
tenofovir was registered only in March 2010.
Objective
To study efficacy and safety Ltd at patients with HIV-
infection and CHB (HIV/CHB).
Methods
12 patients with HIV/CHB (men 10), middle age of 33,5
years, without HAART (CD4 + - 450-650 cells/mm
3),
since 2009 received LdT (600 mg QD). All patients had
HBsAg, HBV DNA. 9 from 12 patients had HBeAg.
Duration of treatment has made 3-12 months.
Summary of results
At all patients had the positive result of therapy with
LdT: 7 patients had disappearance of HBV DNA in 1-6
months; at 1 patient after 3 months of therapy observed
disappearance of HBsAg and appearance anti-HBs and
Ltd has been cancelled. At 5 patients through 6-9
months of treatment is marked a decreasing of level of
HBV DNA on 2-3 log IU/ml. At 4 from 9 patients with
HBeAg observed seroconversion to anti-HBe. In absence
HAART registered fluctuations of level of HIV RNA
was not statistically significant. The adverse events of
therapy with Ltd have not been registered.
Conclusions
Therapy of CHB with Ltd at patients with HIV-infection
was effective: at 58,3 % of patients had disappearance of
HBV DNA, and at 4 from 9 patients with HBeAg
observed seroconversion. Influence of therapy with Ltd
on dynamics of HIV RNA it wasn’t revealed.
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